As molecular mechanisms of 7-MG are known (PARP1/2 and TGT inhibition), a thorough investigation of its anticancer properties could be initiated in vivo, involving various transplantable tumor models and a set of existing drugs as active controls. This evidence concerns the gene PARP1 and neoplasm.